



Metallomics

Metallomic and Lipidomic Analysis of *S. cerevisiae* Response to Cellulosic Copper Nanoparticles Uncover Drivers of Toxicity

Journal:	<i>Metallomics</i>
Manuscript ID	MT-ART-01-2020-000018.R1
Article Type:	Paper
Date Submitted by the Author:	01-Mar-2020
Complete List of Authors:	Winans, Matthew; West Virginia University, Biology Gallagher, Jennifer; West Virginia University, Biology

SCHOLARONE™
Manuscripts

Significance to Metalloomics

Approximately one-third of all proteins and half of all enzymes are predicted to be dependent on a metal ion for structure or function. Proteomic and genetic analysis demonstrate a link between copper and zinc homeostasis. Cellulosic copper nanoparticles are uniquely toxic compared to soluble copper sulfate. The physical, chemical and functional properties of particles on the nanometer scale often differ from their dissolved or larger particle counterparts of the same elemental species. This study elucidates the understanding of the metalloome, metabolome, and the mechanistic drivers during the exposure of carboxymethylcellulose copper nanoparticles.

Metallomic and Lipidomic Analysis of *S. cerevisiae* Response to Cellulosic Copper Nanoparticles Uncover Drivers of Toxicity

Matthew J. Winans and Jennifer E. G. Gallagher*

West Virginia University – Biology Department, 53 Campus Drive LSB 3140, Morgantown, WV, 26506

*Corresponding Author: Jennifer E. G. Gallagher

Keywords: copper, metal, nano, nanotoxicity, nanoparticle, ROS, yeast, lipid, membrane, damage, CMC, carboxymethyl cellulose, cellulose, nanotechnology, antimicrobial, metabolomics, electron microscopy,

Abstract

Nanotechnology is a promising new technology, of which antimicrobial metal nanocomposites are predicted to become valuable in medical and food packaging applications. Copper is a redox-active antimicrobial metal that can become increasingly toxic depending on the target biomolecule's donor atom selectivity and the chemical species of copper present. Mass is the traditional measurement of the intrinsic elemental chemistry, but this practice fails to reflect the morphology and surface area reactivity of nanotechnology. The carboxymethyl cellulose copper nanoparticles (CMC-Cu) investigated in this study have unique and undefined toxicity to *Saccharomyces cerevisiae* that is different from CuSO₄. Cellular surface damage was found in scanning electron micrographs upon CMC-Cu exposure. Further investigation into the lipids revealed altered phosphatidylcholine and phosphatidylethanolamine membrane composition, as well as depleted triacylglycerols, suggesting an impact on the Kennedy lipid pathway. High levels of reactive oxygen species were measured which likely played a role in the lipid peroxidation detected with CMC-Cu treatment. Metal homeostasis was affected by CMC-Cu treatment. The copper sensitive yeast strain, YJM789, significantly decreased cellular zinc concentrations while the copper concentrations increased, suggesting a possible ionic mimicry relationship. In contrast to other compounds that generate ROS, no evidence of genotoxicity was found. As commonplace objects become more integrated with nanotechnology, humanity must look forward past traditional measurements of toxicity.

Significance to Metallomics

Approximately one-third of all proteins and half of all enzymes are predicted to be dependent on a metal ion for structure or function. Copper and zinc homeostasis have mounting proteomic and genetic evidence that suggests a link between the two metals. Cellulosic copper nanoparticles are uniquely toxic compared to soluble copper sulfate. The physical, chemical and functional properties of particles on the nanometer scale often differ from their dissolved or larger particle counterparts of the same elemental species. This study elucidates the understanding of the metallome, metabolome, and mechanistic drivers during the exposure of carboxymethylcellulose copper nanoparticles.

Introduction

Copper is known as a broad-spectrum biocidal towards microorganisms¹⁻³. Since antiquity, copper vessels have been used for disinfection of water and preservation of food against microorganisms⁴, yet humans have a low contact sensitivity from coinage and personal adornment⁵. In general, antimicrobial metals selectively disrupt cell growth. This growth disruption is influenced by the properties of both the metal and the available donor ligands on any biomolecules affected. This antimicrobial metal species damage is spatially localized disrupting membrane function, causing dysfunctional proteins, and DNA damage⁶. Important determinants of metal antimicrobial toxicity are donor atom selectivity, speciation, and reduction potential^{2,6}. Donor atom selectivity is a factor that influences the compatibility between metal and the ligand that is potentially damaged. Speciation is important because the species of metal has a large influence on its bioavailability and reduction potential, for instance, the difference between Cu^{1+} and $\text{Cu}^{2+7,8}$. Moreover, potentially toxic materials have several driving factors including their intrinsic chemistry, surface area reactivity, and morphology; which influence any material's interaction with organisms.

Transition metals, particularly copper and iron, are two that are well known to be reduction-oxidation (redox)-active, but not all metals are active this way. This critically impacts their toxicity because redox-active metals sequentially reduce oxygen through the addition of electrons, forming reactive oxygen species (ROS). In biological systems, finely tuned redox activity facilitates the gain or loss of electrons between two chemical species enabling fundamental processes such as respiration, nitrogen fixation, and photosynthesis⁹. During cellular respiration, the mitochondria produce endogenous ROS as a result of oxygen reduction. This is a consequence of electrons being transferred between complexes to generate an electron potential across the mitochondrial membrane, generating ATP. H_2O_2 and $\cdot\text{O}_2$ are products of transferring electrons to molecular oxygen and progenitors of ROS¹⁰. In addition to molecule damage, it is well established that ROS can also act as a signaling molecule throughout the cell triggering cell signaling proteins, transporters, ion channels, modifying protein kinase, and ubiquitination systems¹¹. A major mechanism of coppers toxicity to microorganisms is the disruption of the plasma membrane's integrity in which the fatty acid composition directly affects their susceptibility to copper in *S. cerevisiae*¹². There is limited research on copper's influence on lipid biology, but copper ions have been shown to interact with synthetic membrane models of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) in an ordered fashion. PC interacts with copper before PE based on the structure of the membrane prevalent phospholipids¹³.

Aqueous copper exists in the particulate, colloidal, nanoparticle, and soluble states, predominately as metal and Cu^{2+} ions^{6,14}. Inside the cell, essential metals are almost never free because of a plethora of transporters, regulatory sensors, and chaperones that confine the metal species and guide metal atoms to specific sites in proteins⁹. Interactions of metal ions with the atoms of ligand donors, such as functional groups of proteins, are strongly selective^{15,16} and have a bias that facilitates the recognition of correct metal¹⁷. Approximately one-third of all proteins and half of all enzymes are predicted to be dependent on a metal ion for structure or function¹⁷⁻¹⁹. Proteins have a somewhat flexible steric selection for their desired metal and their selection is predisposed by an ordered universal preference for essential divalent cations such as copper over zinc²⁰. Copper is the third most biologically abundant transition metal after iron and zinc, and unbalanced metal homeostasis results in the mis-metallation of proteins²¹. When metal homeostasis is unbalanced

1
2
3 some proteins bind incorrect metals, negatively influencing their structure and function. Lowly
4 discriminate biomolecules contribute to ionic or molecular mimicry by binding with metal ions or
5 metal complexes that resemble their correct cofactors². Co-transportation of metals with ligands
6 has also been shown to be a source of metal accumulation²². Yeast cells accumulate surplus metals
7 in vacuoles^{23,24} and intracellular accumulation of metal is routinely the first step in metal
8 poisoning⁶.
9

10
11 The CMC-Cu nanomaterials are considered a hybrid material, composed of copper nanoparticles
12 and cellulose. It is a fibrous, hardy, water-insoluble substance composed of a high molecular
13 weight homopolymer of β -1,4-linked anhydro-D-glucose units that maintain the structure of cell
14 walls in plants²⁵. The high number of Na-carboxyl groups on carboxymethyl (CMC) make it an
15 attractive organic support structure on which to construct copper nanoparticles because it can
16 facilitate copper's reduction and therefore further copper's availability on the cellulose
17 structure^{26,27}. They are synthesized *in situ* and reduced onto available carboxylic groups of
18 carboxymethyl cellulose (CMC) as a template and stabilizer in order to manufacture
19 nanocomposite materials²⁷. These CMC microfibril strands contain the reduced copper
20 nanoparticles (CuNP) that exhibit mostly Cu^{1+} and Cu^0 forms averaging 15 nm in diameter²⁷.
21 CuNPs are built on CMC, forming CMC-Cu. Copper is thought to be slowly released as Cu(I)
22 and then oxidized making Cu(II) available to interact with biological molecules leading to an
23 intrinsic toxicity²⁸. Variations in the copper composition and cellulose biopolymer have been
24 successfully synthesized resulting in changes to their interaction with microorganisms²⁹⁻³².
25 CMC-Cu sensitivity mirrors the sensitivity of genetically diverse yeast exposed to soluble copper
26 in CuSO_4 form²⁸. When copper oxide is presented to yeast on the nanoscale, it is approximately
27 60-fold more toxic than its soluble counterpart³³. Earlier work established that the derivative of
28 cellulose and how the microorganisms were exposed, whether in liquid or what material the
29 CMC-Cu was embedded in, made a difference in the kinetic and biological reaction³⁰. Previous
30 studies in higher eukaryotes found that CuO NPs have a "Trojan horse mechanism" that induces
31 endocytosis and causes DNA damage by the intracellular ionic release of copper³⁴. CuNPs
32 appear to target the cell membrane to cause cellular death by loss of membrane integrity³⁵.
33
34
35
36
37

38 This study builds upon the proteomic and genetic evidence found in the first exposures of CMC-
39 Cu to *S. cerevisiae*²⁸ by furthering the toxicological profile of the cellular response to include the
40 metallomic and metabolomic aspects. Mounting evidence lead to the hypothesis that lipid
41 interaction of the cellular membrane is the primary process by which CMC-Cu impart their
42 nanotoxicity. These findings align with previous reports suggesting that copper causes a loss in
43 the cellular membrane's integrity^{6,36}. Copper nanoparticles derived from CMC-Cu treatments
44 decrease cellular viability, which unlike soluble copper sulfate, is rescued by glutathione, but not
45 its precursor N-acetylcysteine (NAC)²⁸. This is indicative of the exogenous nature of CMC-Cu's
46 primary nanotoxicological process. This original research investigated the influence of CMC-Cu
47 exposures to *S. cerevisiae* on metal homeostasis, ROS production, lipid interaction, cellular
48 morphology, and genotoxicity.
49
50

51 **Methods and Materials**

52 **Yeast Growth and Treatment Conditions**

53
54
55
56
57
58
59
60

1
2
3 All *S. cerevisiae* yeast strains were grown in either YPD (yeast rich media, 1% yeast extract, 2%
4 peptone, 2% dextrose) or YM (yeast minimal media, 0.67% yeast nitrogen base without amino
5 acids, 2% dextrose) supplemented with amino acids needed to complement any auxotrophic
6 markers (histidine, uracil, leucine, and methionine (HULM) or lysine (HULK)). Yeast strains were
7 maintained indefinitely at -80°C in a 15% glycerol solution, temporarily at 4°C on solid YPD or
8 YM agar plates, and readily by log-phase growth at 30°C in YPD or YM liquid media. Growth
9 was measured by optical density at 600nm.
10
11

12 Yeast were treated with soluble copper at 400 μM by copper sulfate addition. Yeast were treated
13 with copper nanoparticles at 157 μM copper by CMC-Cu addition. Glutathione (GSH) was
14 supplied at 4.16 mM in the media. The concentration of CMC in both the CMC-Cu and CMC was
15 10 $\mu\text{g mL}^{-1}$. Exposure of 157 μM copper in NPs is effective as 400 μM copper sulfate in inhibiting
16 the growth of YJM789, the copper sensitive strain²⁸. These growth and treatment conditions were
17 used to highlight the increase in toxicity from the enhanced delivery of Cu to the cytoplasm.
18
19

20 Cellular Metals

21 Yeast strains BY4741 and YJM789 were grown in triplicate until log-phase in YM+HULM
22 (histidine, uracil, leucine, and methionine) or YM at 30°C, respectively. Yeast cells were treated
23 with 400 μM CuSO₄ or 157 μM CMC-Cu for 90 minutes. An equal number of cells were
24 determined by optical density at 600 nm to collect equivalent to 5 optical density units (ODu) of
25 cells. These samples were centrifuged and washed twice with distilled water. One ODu was
26 separated for protein quantification. Samples were split, frozen in liquid nitrogen, and stored at -
27 80°C. Soluble protein concentration was determined via Bradford assay as previously published
28 ²⁸. For inductively coupled plasma – optical emission spectroscopy (ICP-OES), the cell pellets
29 were treated with 600 μL of concentrated HNO₃ and 200 μL of 30% H₂O₂ for digestion³⁷. These
30 solutions were transferred to glass tubes and placed in a boiling water bath for 2 hours until clear.
31 The liquids were filtered via syringe and readjusted to their original volumes with distilled water.
32 Samples were analyzed at 327.395 nm for Cu and at 213.857 nm for Zn. Metal concentrations
33 were given in mg ml⁻¹ and normalized to soluble protein concentration for each sample. Three
34 biological replicates were used in this protocol. ANOVA statistical analysis was utilized in
35 determining significance with a Tukey-HSD post-hoc analysis. An alpha of 0.05 was used as the
36 cutoff for significance. SAS JMP (SAS JMP Pro Version 13, SAS Institute Inc., Cary, NC, USA)
37 was used for statistical software. The standard error of the mean was used in graphing error bars.
38 The one-way ANOVA statistical analysis was performed via Tukey HSD post hoc analysis
39 (p=0.05). Samples that do not share a letter are significantly different. Samples that share a
40 common letter are not significantly different.
41
42
43
44
45

46 Cellular ROS

47 Cellular ROS detection assay was carried out with modification to an existing protocol³⁸. The 2,7-
48 dichlorofluorescein diacetate (DCFDA) cellular ROS detection assay kit was ordered from Abcam
49 (ab113851). Briefly, yeast strain BY4741 was grown to stationary-phase in YPD supplemented
50 with DCFDA without light at 30°C. Cultures were centrifuged and washed in phosphate-buffered
51 solution before being resuspended YM+HULM to a final OD₆₀₀ of 0.7. Yeast were treated for 90
52 minutes, CMC-Cu at 157 μM and CuSO₄ at 400 μM , and controls, H₂O₂ at 489 μM , in a 96 well
53 black bottom microplate from Greiner Bio-One for end-point fluorescence measurement at Ex/Em
54 = 485/535 nm on a SpectraMax Gemini XPS Fluorescence Microplate Reader from Molecular
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Devices. Five biological replicates were used in this protocol. ANOVA statistical analysis was utilized in determining significance with a Tukey-HSD post-hoc analysis. An alpha of 0.05 was used as the cutoff for significance. SAS JMP (SAS JMP Pro Version 13, SAS Institute Inc., Cary, NC, USA) was used for statistical software. The standard error of the mean was used in graphing error bars.

Lipid Peroxidation

Lipid peroxidation was colorimetrically measured by assessing the major byproduct of lipid peroxidation, malondialdehyde, in a Thiobarbitic Acid Reactive Substances assay (TBARS). The OxiSelect™ TBARS assay kit (STA-330) was obtained from CellBioLabs, Inc, San Diego, CA, USA. Yeast strain YJM339 was grown in triplicate until log phase in YM at 30°C. Yeast cells were harvested at a final OD₆₀₀ of 0.7, treated with 400 μM CuSO₄, 157 μM CMC-Cu, or 498 μM H₂O₂ for 90 minutes. A kit-supplied SDS lysis solution (Part No. 233003) was incubated within both the samples and the malondialdehyde (MDA) standards (Part No. 233001) at 1:1 ratio totaling 200 μl for five minutes at 23°C. 250 μl of thiobarbitic acid reagent (5.2 mg mL⁻¹ at pH 3.5) (Part Nos. 233002 & 233004) was added to each sample and incubated at 95°C for 50 minutes. Samples were cooled in an ice bath for five minutes before 15 minutes of centrifugation at 3,000 g. The supernatant was harvested and aliquoted for duplicate technical spectrophotometric measurement in a TECAN Infinite 200 pro microplate reader at 532nm absorbance. TBARS levels were determined from an MDA equivalence standard curve ranging from 0 to 125μM. ANOVA statistical analysis was performed with Tukey-HSD post-hoc analysis. An alpha of 0.05 was used as the cutoff for significance. SAS JMP (SAS JMP Pro, Version 13, SAS Institute Inc., Cary, NC, USA) was used for the construction of the whisker-box plots.

Electron Microscopy

Yeast strain BY4741 was grown in YM+HULM until log-phase at 30°C. Cells were treated with CMC-Cu at 400 μM for 90 minutes before 6 ml were harvested by centrifugation for 4 minutes at 3,000 g. The supernatant was pipetted off and the cells were resuspended in 500 μl of paraformaldehyde (14%) for one hour at room temperature. Fixed cells were washed once and resuspended in 0.1 M KPO₄/1.2 M sorbitol buffer for storage at 4°C. Within 72 hours in the WVU Electron Microscopy Facility, the cells were fixed with 2.5% glutaraldehyde for one hour before washing thrice with PBS for 15 min each. Samples were then aliquoted into Eppendorf tubes for either SEM or TEM processing and imaging.

The cells were dehydrated stepwise by 15 min ethanol baths starting at 30% and increasing to 50%, 70%, 90%, and finally, 100%. The 100% ethanol bath was repeated three times. Yeast cells were pelleted, and the supernatant was discarded after each ethanol addition. Samples were submerged in hexamethyldisilazane to dry the cells for 15 minutes before allowing the cells to air-dry overnight in a fume hood with the caps of the Eppendorf tubes slightly open. Samples were adhered to pins by carbon tape and sputtered with gold and palladium (60:40) for 150 seconds at 18kV with rotation. A Denton Desk V Sputter and Carbon Coater were used in sputtering samples. Images were captured on a Hitachi S-4700 Scanning Electron Microscope.

DNA Damage

Damage to DNA and chromosomes was assessed by pulse-field gel electrophoresis (PFGE). Yeast strain BY4741 was grown to log phase in YM+HULM media at 30°C. Cells were treated with

1
2
3 H₂O₂ at 489 μM or CMC-Cu 400 μM up to 90 minutes. One OD_{600nm} unit of yeast cells was
4 harvested by centrifugation in conical tubes at time points of 5 min, 15 min, 30 min, 60 min, and
5 90 min. The sample supernatant was removed and frozen in liquid nitrogen for storage at -80°C,
6 sample processing occurred within 24 hours. Cells and zymolase enzymes at a final concentration
7 of 0.05 μg/ml were mixed 1:1 with 2% low melting agarose gel diluted in 0.5x TBE to obtain 1
8 OD unit per plug. Plugs were made in a Bio-Rad disposable plug mold via heat block set to 50°C
9 with a cut off pipette tip to facilitate the agarose mixing. The solidification of agarose plugs
10 occurred for 15 min at 4°C. To digest the cell wall, 1 ml of plugs were placed in 5 ml of M/15 PBS
11 supplemented with zymolase and incubated for 1 hour at 37°C without agitation. Plugs were
12 washed with a wash buffer (20mM Tris, 50mM EDTA, pH 8). The protein was digested by adding
13 a proteinase K buffer (30mM Tris, 50mM EDTA, 1% SDS, 0.125μg/ml proteinase K, pH 8) and
14 incubating at 50°C overnight. Plugs were washed four times for 1 hour each at 23°C. Plugs were
15 trimmed to ¾ original size, positioned onto the comb ends and adhered with one droplet of low
16 melting agarose. A 1.5% PFGE gel was made using 0.5x TBE and Bio-Rad PFGE agarose by
17 casting into a mold with the comb in position. After the gel solidified, the comb was removed, and
18 the gel was placed into a Bio-Rad CHEF DR II system filled with 0.5x TBE equipped with a water
19 cooler. Electrophoresis of the experimental gel occurred for 24 hours at 14°C with a switch time
20 of 60-120 seconds and set to 6v/cm. The gel was removed, stained in a 0.125 μg/ml ethidium
21 bromide bath for 10 minutes, and destained with distilled water for one hour before imaging at
22 254nm. Pictures were manipulated in Microsoft PowerPoint solely to straighten running lanes for
23 added clarity.
24
25
26
27
28

29 **Exploration of Lipidome**

30 Lipid metabolites were assessed in *S. cerevisiae* YJM789, grown in YM to exponential phase (OD
31 0.4 – 0.6), and then treated or not for 90 minutes. Six independent biological replicates were
32 performed. Five optical units of cells were harvested, washed with MQ (milliQ) water, and flash-
33 frozen in liquid nitrogen for storage at -80°C until extraction within 24 hours. Lipid and polar
34 metabolites were extracted with 6 ml of a 1:2:0.8 mixture of chloroform: MeOH: H₂O, following
35 a modified version of a published protocol^{39,40}. Glassware was used to avoid polymer
36 contamination. Extraction occurred in 15 mL Kimble™ Kontes™ KIMAX™ reusable High
37 Strength Centrifuge Tubes from Fisher Scientific. HPLC-grade chloroform and methanol were
38 from Sigma-Aldrich. Six replicates of 3ml each were harvested for their lipid phase and dried
39 under nitrogen gas. The lipid phases were re-suspended in 500 μL 1:1 chloroform: MeOH and
40 these extracts were stored at -20°C until analysis within 48 hours.
41
42
43

44 Lipid extracts were analyzed by direct injection using a Thermo Fisher Scientific QExactive, with
45 an ESI (electrospray ionization), using positive and negative modes. For lipid compounds in
46 positive mode, the injection speed was 10 μL/min, the scan range: 150.0 – 2,000.0 m/z, no
47 fragmentation, 140,000 resolution, 1 microscan, AGC target 5 x 10⁵, maximum injection time of
48 100, sheath gas flow rate of 15, aux gas flow rate of 11, no sweeping gas flow, spray voltage of
49 3.50 kV, capillary temperature of 300°C, S-lens RF level: 25.0. These same parameters were kept
50 for lipid compounds in negative mode except for a spray voltage of 3.20 kV. For each sample, a
51 total of 50 scans were obtained and averaged with Thermo Scientific Xcalibur 2.1 SP1. Averaged
52 spectra in the positive and negative mode were processed with xcms 3.2.0⁴¹. Peaks were identified
53 within each spectrum using the mass spec wavelet method from the MassSpecWavelet 1.46.0 R
54 package⁴². Peaks were grouped via the Mzclust method, followed by group ChromPeaks. All
55
56
57
58
59
60

features were plotted and visually inspected. Intensity values of each sample feature were obtained via the featureValue method using the integrated signal area for each representative peak per sample. Feature intensity and feature definition tables were saved as CSV files. Features were identified via MetaboSearch 1.2⁴³. The query ID list was comprised of the average m/z values for each feature in positive or negative mode with 5 ppm of error and was searched against the four databases available online in the program: Human Metabolome Database (HMDB)⁴⁴, Metlin⁴⁵, Madison Metabolomics Consortium Database (MMCD)⁴⁶ and LipidMaps⁴⁷. Identifications were manually cross-referenced with Yeast Metabolome Database (YMDB)⁴⁸ and PubChem⁴⁹. Feature intensity tables were composed of only identified features from positive and negative modes with at least five biological replicates. MetaboAnalyst⁵⁰ was used for statistical analysis, data normalization to the intensity of all features, and generation of the graphical figures. The experiment was repeated twice with consistent results.

Results and Discussion

Metal Homeostasis

To explore compromised metal homeostasis induced by CMC-Cu exposure, the intracellular metal concentrations were quantified. Experimentally, the Zrt1 protein levels in copper resistant yeast S288c increases 2-fold in response to copper perturbation, suggesting some responsive role for the Zrt transporters²⁸. Cellular copper and zinc levels were analyzed via Inductively Coupled Plasma – Optical Emission Spectroscopy (ICP-OES) after exposure to 400 μM CuSO_4 or 157 μM CMC-Cu which results in nearly equal growth inhibition of the copper sensitive strain²⁸. During normal growth of the sensitive clinical isolate YJM789 in YM, ICP-OES analysis measured 0.043 mg mL^{-1} Cu, standard error (SE) 0.011 (Figure 1A and Figure S1). The resistant lab isolate, BY4741 is derived from the S288c and contains additional auxotrophic markers. The copper content in BY4741 under normal growth conditions was undetectable (Figure 1B). Unsupplemented YM media supplies 0.16 nM Cu in the growth medium. After CuSO_4 addition, copper levels increased for each strain. The level of copper in YM is not optimal for BY4741 because the addition of 50 μM CuSO_4 increases growth²⁸, suggesting that BY4741 is copper deficient in standard growth media. With CuSO_4 , copper levels rose but to differing degrees. YJM789 had 1.223 mg mL^{-1} Cu, SE




Figure 1 Copper and Zinc Metal Homeostasis Measured by Inductively Coupled Plasma – Optical Emissions Spectroscopy During CMC-Cu Toxicity. Sensitive strain YJM789 (A) and resistant strain BY4741 (B) were harvested after 90-minute treatments with CMC-Cu or CuSO_4 . (A) YJM789 has a significant increase in cell-associated copper with CMC-Cu treatment and a decrease in cellular zinc. (B) BY4741 showed an increase of cellular copper with CMC-Cu treatment, no change to zinc concentrations. Statistical analysis performed via one-way ANOVA with a post hoc Tukey HSD analysis ($p=0.05$). ND= Not detected.

0.011 and BY4741 had 0.837 mg mL⁻¹ Cu, SE 0.029. Copper levels increased in the resistant strain, BY4741, to 2.541 mg mL⁻¹ Cu after CMC-Cu treatment. Tukey-Kramer honest significance difference (Tukey-HSD) post-hoc statistical analysis showed no statistical difference between copper levels of either CMC-Cu or CuSO₄ treated cells of either strain with one exception (Table 1). The sensitive strain, YJM789, increased its copper concentration to 7.230 mg mL⁻¹ Cu, SE 1.086 after treatment with CMC-Cu. Intracellular copper concentrations were only significantly increased when YJM789 was exposed to CMC-Cu (p<0.001).


Table 1. Connecting Letters Statistical Report for Copper and Zinc Levels by Strain and Treatment. Statistical analysis performed via one-way ANOVA with a post hoc Tukey HSD analysis (p=0.05). Samples that share a common letter are not significantly different. Samples that do not share a letter are significantly different.

Zn		
	YJM789	BY4741
YM	A	A
CMC-Cu	B	A,B
CuSO₄	A,B	A,B

Cu		
	YJM789	BY4741
YM	C	A,B,C
CMC-Cu	A	A,B
CuSO₄	B	B

Zinc is a divalent transition metal that binds to ligands less stably than copper according to the Irving-Williams series²⁰. The concentration of cellular zinc significantly decreased from the YM baseline of 0.632 mg mL⁻¹ zinc for yeast strain YJM789 in response to CMC-Cu treatment, resulting in a cellular concentration of 0.344 mg mL⁻¹ Zn, SE 0.0449 (p=0.028). In response to CMC-Cu treatment, the sensitive strain, YJM789, increased levels of copper while decreased the levels of zinc. This evidence suggests that metal homeostasis of zinc and copper influences the toxicity of CMC-Cu. Zinc metallates 582 potential zinc-binding proteins contributing to the structure and function of approximately ~ 10% of the total yeast proteome²¹. *S. cerevisiae* yeast have a minimum zinc quota of ~10⁷ atoms/cell⁵¹, most of which is tightly controlled allowing a low level of labile zinc⁵²⁻⁵⁴. This labile zinc is maintained via intercellular storage in organelles, in the cytosol by dynamic metallothioneins that buffer redox activity, and in intracellular yeast vesicle compartments that resemble mammalian zincosomes⁵⁵⁻⁵⁷. The cellular zinc levels of the other conditions and strains were all statistically the same. After CuSO₄ treatment, YJM789 zinc levels decreased from 0.632 mg mL⁻¹ to 0.46 mg mL⁻¹. BY4741, the copper resistant strain, in YM had 0.562 mg mL⁻¹ of zinc. CMC-Cu treatment did not significantly change the levels of zinc nor did CuSO₄ in the copper resistant strain. The levels of zinc in YJM789 treated with CMC-Cu decreased to nearly half compared to the yeast grown in YM. The findings presented here align with literature reports implicating a role for zinc in copper nanoparticle toxicity²⁸. The compromised metal homeostasis observed in YJM789 is likely involved in this strain sensitivity towards copper. One possible explanation of the relationship seen between falling Zn and increasing Cu levels involves the stability of transition-metal complexes as described by the Irving-Williams series. In this trend, divalent transition metals create an increasingly stable complex

resulting with copper as the most favored. The ligands selection bias is as follows: $Mn^{2+} < Fe^{2+} < Co^{2+} < Ni^{2+} < Cu^{2+} > Zn^{2+}$ and this is related to size and charge of the metals. As seen in other reports, one way this unbalance may propagate is through ionic mimicry, where zinc or other transporters select copper instead of zinc⁵⁸. This chemical tendency between metal atoms not only is a factor of CMC-Cu toxicity but also is a factor in antimicrobial metal toxicity. The mechanism by which the different forms of Cu affect Zn levels are unclear, and this is likely involved with enhanced delivery of Cu to the cytoplasm in the YJM789 strain²⁸. The high-affinity zinc transporter, Zrt1, has been previously shown attribute to the Cu resistance in mutational analysis and QTL analysis found the low-affinity zinc transporter, Zrt2, that has five amino acid polymorphisms between the two yeast strains that contributes to Cu sensitivity of YJM789²⁸. Studies investigating copper uptake and kinetics found that the kinetic uptake for copper in *S. cerevisiae* is $V_{max} = 0.21 \text{ nmol Cu min}^{-1} (\text{mg protein})^{-1}$ with a $K_m = 4.4 \mu\text{M}$ ⁵⁹ and that accumulation of Cu decreases in the presence of Zn^{2+} ⁶⁰. The zinc transporters of YJM789 are likely participating in an ionic/molecular mimicry mechanism importing CMC-Cu. The spatial concentration of CuNPs from CMC-Cu on the cellular surface may influence the difference in ionic mimicry between the two forms of copper in this research.



giving rise to incompletely reduced forms of molecular oxygen (O_2) which yield hydrogen peroxide (H_2O_2) and hydroxyl radical ($\cdot O_2$). In the presence of a redox-active metal, Fenton reaction driven autooxidation occurs. To measure intracellular ROS, a fluorometric assay utilizing 2,7-dichlorofluorescein diacetate (DCFDA) was measured at the standard 90 min treatment (Figure 2A) and over time (Figure S2) which showed the differences in ROS between treatment groups as they biologically interacted with the perturbations. CMC-Cu treatments of 157 μM produced high amounts of ROS measured at 11.35 fluorescence (FC), SE 0.26 (Figure 2A); nearly double the endogenous ROS levels in YM. Hydrogen peroxide (H_2O_2) treatments at 489 μM produced similar levels of intracellular ROS levels of 10.38 FC, SE 0.26. Although soluble and nano-copper treatments were determined to inhibit growth at similar levels²⁸, the 400 μM treatment of $CuSO_4$ did not produce significant enough levels of ROS via this DCFDA assay. The yeast used here, BY4741, tolerated 400 μM $CuSO_4$ well. It is likely that increased ROS detection would occur by exposing this yeast to increased levels of $CuSO_4$, which would increase the growth inhibition of this resistant strain. $CuSO_4$ treatments produced intracellular ROS levels of 5.62 FC, SE 0.26 which was similar to the level detected in untreated control cells. ROS was detected at 5.5 FC, SE 0.26 in untreated cells (YM). Post-hoc statistical analysis via Tukey-Kramer honest significance difference (Tukey-HSD) analysis defined three detection levels between the samples, a low-level ROS group of $CuSO_4$ / YM and two different high-level ROS groups composed of either H_2O_2 or CMC-Cu. Reduction potential is a key factor when determining the toxicity of antimicrobial metals. In bacteria, there have been at least three mechanisms suggested for the increased ROS produced via metal poisoning. They include catalyzing Fenton chemistry^{61,62}, disruption of iron ligands such as Fe-S clusters that release redox-active $Fe^{63,64}$, and thiol mediated reduction of metal species^{62,65}. Importantly, the oxidation of cellular thiols occurs via Cu-S covalent bonding which leads to disulfide bonds in proteins, thus depleting critical antioxidants including glutathione, ultimately preventing cellular repair^{2,66-68}. The glutathione tripeptide molecule contains thiol ligand groups in their cysteine amino acid. This sulfur-containing molecule reduces copper by donating an electron to copper, which results in oxidation of the thiol group inducing a disulfide bond between cysteines of two glutathione molecules. While in yeast, $CuSO_4$ toxicity is rescued by both glutathione and precursor N-acetylcysteine, but CMC-Cu toxicity is only rescued by glutathione²⁸. Several adaptations and resistance mechanisms in *S. cerevisiae* are known, of which the intracellular sequestration of Cu and the yeast strain resistance is largely predicted by the variation in copy number metallothionein *Cup1*. This copy number variation and resistance is seen in the type and sequence strain, S288c^{69,70}, from which the BY4741 strain used here is derived. This evidence, together with the findings on intracellular ROS suggesting that the reduction potential of CMC-Cu, contributes to its unique nanotoxicity.

Genotoxicity

In an approach to identify the primary process and kinetics of CMC-Cu induced ROS damage to the yeast cells, the possibility of DNA damage was explored via a timed pulse-field gel electrophoresis (PFGE). As DNA is damaged, the accumulation of breaks causes the distinct chromosomal bands to be lost. The more ambiguous the chromosomal bands are in the PFGE, the more DNA damage has occurred. DNA damage by ROS has been well documented and implicated in mutagenesis and carcinogenesis⁷¹, but there remains some discussion about its role in the primary damaging process. Hydrogen peroxide and the superoxide anion damage DNA by creation of the hydroxyl radical and singlet oxygen which are energetic enough to have a direct effect on DNA^{72,73}. CMC-Cu at 157 μM caused little to no DNA damage over this study's typical 90-minute

1
2
3 treatment when measured qualitatively by inspecting the chromosomal band integrity in the PFGE
4 gel (Figure 2B). The chromosomal band integrity, band intensity, and background smearing of
5 CMC-Cu treated cells with those of the YM control were very similar in pattern. When treated
6 with 489 μM of H_2O_2 over time, a shift in the chromosomal band integrity was seen starting at the
7 15-minute mark and progressing until the 90-minute mark where all chromosomal band integrity
8 was lost to DNA fragmentation represented as smearing across the gel. Hydrogen peroxide⁷⁴ and
9 copper at moderately toxic concentrations induce apoptosis in *S. cerevisiae*⁷⁵. DNA fragmentation,
10 phosphatidylserine externalization, and chromatin condensation are typical markers of yeast
11 apoptosis⁷⁶. Highly toxic levels of Cu induce necrosis from which the mitochondria has been
12 implicated to play a role⁷⁵. With these findings in sight, the hypothesis that CMC-Cu treatment
13 under these conditions lacked DNA fragmentation, but induced lipid damage to the cellular
14 membrane damage was formed.
15
16
17

18 **Lipid Peroxidation**

19 Aside from DNA, another target of cellular damage is the lipid membrane of the cell, and a
20 compromised cellular membrane is a major action of antimicrobial copper. This investigation
21 aimed to determine if lipid peroxidation was the primary process of CMC-Cu induced ROS
22 damage to *S. cerevisiae*. ROS-induced lipid peroxidation⁷⁷⁻⁷⁹ and *S. cerevisiae*'s cellular fatty acid
23 composition-dependent susceptibility to copper¹² was considered in forming this hypothesis.
24 During lipid peroxidation, byproducts are formed of which malondialdehyde (MDA) is a
25 convenient biomarker for lipid peroxidation^{80,81}. Thiobarbituric acid (TBA) reacts with MDA
26 forming a deeply colored chromogen fluorescently red adduct TBA-MDA⁸². By utilizing this
27 reaction, lipid peroxidation was investigated by measuring the MDA-TBA adduct in a fluorescence
28 assay known as a thiobarbituric acid reactive substances assay (TBARS). Dunnett's post-hoc
29 statistical analysis found that the CMC-Cu, CuSO_4 , and H_2O_2 treatments all induced lipid
30 peroxidation compared to the YM control media (Figure 2C). CMC-Cu treated cells analyzed via
31 the TBARS assay produced the greatest fluorescence measuring at 8.03 μM MDA and within the
32 biological replicates there was a wide-range. During this experiment a relatively large amount of
33 variation between the CMC-Cu exposures was found. This is likely related to particle size
34 distribution and degree of agglomeration of the particles. Levels of lipid peroxidation caused by
35 hydrogen peroxide and copper sulfate treated cells were very similar, measuring 5.60 μM and 5.47
36 μM MDA, respectively. These findings supported previous reports of copper's toxic interaction
37 with cell membranes^{13,36}. The control sample in YM media measured 2.12 μM MDA. Unsaturated
38 fatty acids are a major target of ROS that results in a cyclic reaction^{83,84} generating lipid radicals
39 and toxic lipid hydroperoxides^{73,85}. Hydroperoxides are unstable in the presence of metals and they
40 are the primary product of lipid peroxidation. They attach to lipids such as free fatty acids,
41 triacylglycerols, sterols, and phospholipids. *In vivo* decomposition of these compounds occurs via
42 the reduction, in part enzymatically, by glutathione peroxidase typically using glutathione as a
43 reductant⁸². This process ultimately leads to loss of membrane integrity and generation of
44 aldehydes that can cause distant and localized lipid peroxidation^{86,87}. The evidence that CMC-Cu
45 and CuSO_4 initiated lipid peroxidation supports the hypothesis that the primary process of CMC-
46 Cu induced ROS damage to *S. cerevisiae* is lipid peroxidation.
47
48
49
50
51
52

53 **Lipid Profiling**

54 This study's results indicate that CMC-Cu induced ROS facilitated lipid peroxidation, but to
55 further define the details of CMC-Cu nanotoxicity an untargeted exploratory metabolomics
56
57
58
59
60

assessment was employed. By utilizing a gas chromatography with electron spray ionization mass-spectrometry (GC-ESI-MS) methodology the lipidomics aspect proved most interesting. Lipid extracts analyzed in the positive and negative modes of ESI-MS provided 610 potential features that were chiseled down to yield 105 tentative structure confidence level annotated compounds (Table S1). These were used as variables in the statistical analysis performed in MetaboAnalyst 4.0. A partial least squared discriminant analysis (PLS-DA) technique was adequate in discriminating samples into their treatment groups of YM, CMC-Cu, CuSO₄, and CMC. A loadings matrix was made for the PLS-DA (Table S2). A PCA score plot, loading plot, and statistical ANOVA analysis was produced (Figure S3), but the PCA did not provide as good of separation as the PLS-DA. Using three components, a clear separation between all of the treatment groups was found. By using 2 components, 1 and 2, the PLS-DA had an overlap of the YM control and CMC-Cu treatment (Figure 3A). With components 1 and 3, the PLS-DA had an overlap of




Figure 3 Lipid Metabolic Profiling in Response to CMC-Cu Treatment. (A) Partial least squares discriminant analysis (PLS-DA) showing component 1 and component 2 separated all treatments but YM and CMC-Cu. (B) PLS-DA showing component 1 and component 3 separated all treatments but YM and CMC-Cu, as well as CMC-Cu and CuSO₄. Taken together, components 1, 2, and 3 provide a 3-dimensional separation of all treatments based on their lipid profiles. (C) Heatmap of the top 10 metabolites used in profiling yeast treatment groups. Samples are divided into columns, compounds are divided by rows, and the color is indicative of relative abundance. Which was calculated via MetaboAnalyst hierarchical heatmap clustering analysis (clustering distance using euclidean, and clustering algorithm using ward D). (D) Quantitative growth assays of BY4742 (wildtype) and *scw10* isogenic mutant in YM, YM+CMC-Cu, and YM+CMC-Cu with glutathione (GSH). The average of four biological replicates were graphed with standard error after 24 hours of growth.

1
2
3 CMC-Cu and CuSO₄ treatments (Figure 3B). A permutation test was administered that showed the
4 supervised method did not overfit the data, enabling interpretation of the results, $p < 0.001$. This
5 result is suggestive of the similarity between soluble copper toxicity but also supportive of the
6 unique nature of the CMC-Cu nanotoxicity. Component 1 explained 17.8% of the variance,
7 component 2 explained 15.7%, and component 3 explained 27.7% of the variance between samples.
8 The heatmap (Figure 3C) of the top 10 compounds averaged per treatment groups showed the
9 cellular membrane phospholipids phosphatidylethanolamine (PE) and phosphatidylcholine (PC)
10 increased in relative abundance for CMC-Cu treatments. A whole lipidome heatmap was also
11 generated (Figure S4). *In vitro* studies have shown that copper ions interact with synthetic
12 membrane models in an ordered fashion first with PC, then PE based on the structure of the
13 membrane prevalent phospholipids¹³. Moreover, a study on heavy metals interaction with the
14 mycelia lipids of *P. marquandii* utilized high performance liquid chromatography – tandem mass
15 spectroscopy (HPLC-MS/MS) to find the ratio of PE:PC changed, increasing the PC content upon
16 exposure to copper ions⁸⁸. PC and PE composition responded to CMC-Cu and CuSO₄ exposure,
17 albeit in opposing fashion. Unexpectedly, CMC had a depleting effect on lipid composition. PC
18 and PE are the chief membrane lipid components from which their composition influences
19 physico-chemical properties altering basic biological function in yeast such as cell growth,
20 budding, membrane trafficking, and other formations^{89–91}.

21
22
23
24
25 The biosynthesis of fatty acids/ acyl chains starts with the conversion of acetyl-CoA into malonyl-
26 CoA from which the acetyl chain develops mainly C16:0 and C18:0 before desaturation in the
27 endoplasmic reticulum (ER) of *S. cerevisiae*⁹². This acyl-CoA pool can be then converted into bulk
28 phospholipids through various pathways involving the ER and mitochondria⁸⁹. The Kennedy
29 pathway allows PE and PC formation from acyl-CoA and triacylglycerols (TG) pools. This study
30 found that CMC-Cu treated cells depleted TG reserves (Figure S4) and increased important PE
31 and PC levels (Figure 3), suggesting a disruption in lipid homeostasis. TGs stored in lipid droplets
32 protect lipid homeostasis by balancing fatty acid saturation⁹³ and serving as a base for phospholipid
33 metabolism⁹⁴. When needed, TGs are hydrolyzed to provide building blocks for membrane lipid
34 synthesis, delivering a quick response to changing environmental conditions⁹⁵. TG can be
35 converted to PC and PE through the Kennedy pathway^{89,95}. These results support the hypothesis
36 that CMC-Cu treated cells are depleted of their protective TG content through an increase in PC
37 and PE membrane production.

38
39
40
41 Interestingly, in CMC-Cu treated yeast relatively high malonylcarnitine levels were found, a
42 metabolite involved with the transportation of long-chain fatty acids into the mitochondria (Figure
43 3C). Increased levels of malonylcarnitine are indicative of fatty acid oxidation disruption and
44 mitochondrial respiratory chain failure^{96–100}. Cellular copper is distributed throughout the entire
45 cell and a pool of bioavailable copper is also present within the mitochondria¹⁰¹, enabling
46 mitochondrial metallation reactions. Formation of the Cu centers bound within cytochrome c
47 oxidase (CcO) occurs in the mitochondrial inner membrane space (IMS) during which two copper-
48 binding subunits of CcO become metallated¹⁰². The detection of relatively high levels of
49 malonylcarnitine further suggests that lipid damage is a primary target of the yeast cell damage, as
50 this metabolite is indicative of fatty chain transportation disruption. Additionally, the amino-sugar
51 fucosamine also increased in relative abundance during CMC-Cu treatment. Other amino-sugars
52 such as fructosamine have been shown to complex with redox-active metals, chelating copper,
53 iron, and nickel metals displaying some antioxidant aspects^{103–105}, although the research on
54
55
56
57
58
59
60

1
2
3 fucosamine is still in preliminary stages. Primary metabolites were also extracted and analyzed by
4 GC-MS techniques but changes in the metabolism could not be used in a discriminating analysis
5 without overfitting the data (data not shown). Together this lipid profiling and TBARS assay
6 support lipid damage as a primary target of CMC-Cu induced nanotoxicity.
7
8

9 To assess how perturbations in lipid and cell wall metabolism could affect cell growth, quantitative
10 growth of yeast containing knockouts of several candidate genes was measured. From the
11 proteomics measurements, proteins that had levels change more than two-fold in the presence of
12 CuSO₄ were selected²⁸. We selected candidates that had known roles in oxidative stress, lipid
13 metabolism, and cell wall synthesis. Sod2 is the mitochondrial superoxygen dismutase¹⁰⁶. Ach1,
14 a CoA transferase and hydrolase, is expressed in the mitochondria when grown on nonfermentable
15 carbon sources¹⁰⁷. Opi3 synthesizes phosphatidylcholine¹⁰⁸. Mho1 is repressed by Opi1 when
16 inosine and choline is present and is synthetically lethal with *PLC1* deletion which encodes a
17 phospholipase C¹⁰⁹. Gpx2, a phospholipid hydroperoxide glutathione peroxide, functions during
18 oxidative stress to neutralize hydroperoxides¹¹⁰, Cts1, an chitinase that aids in separation of cell
19 walls after mitosis¹¹¹, is also regulated by Ace2, a copper responsive transcription factor¹¹². Scw10
20 is localized to the cell wall and resembles glucanases¹¹³. Each knockout strain was grown in
21 YM+HULK to log phase and then diluted into media containing YM, YM with CMC-Cu, and
22 CMC-Cu with glutathione and then monitored for 24 hours (Figure 3D). In the BY4742
23 background, yeast growth was not slowed at 24 hours. The addition of CMC-Cu did not change
24 the growth. However, the addition of glutathione allowed yeast to grow to a higher density,
25 suggesting that even under standard growth conditions yeast were under oxidative stress. Of all
26 the mutants tested only the *scw10* mutant showed increased growth when CMC-Cu was added.
27 The standard yeast media does not provide optimal levels of copper for growth of yeast from the
28 BY background²⁸. The loss of Scw10 protein from the cell wall may alter the association of the
29 CMC-Cu with the cell wall. In YJM789 yeast, Scw10 increases 1.5 log₂fold when treated with
30 CuSO₄ while the copper resistant strain Scw10 only increased 0.78 log₂fold. The six other mutants
31 in lipid and redox metabolism lack of a growth phenotype could be attributed to the robustness of
32 overlapping pathways to response to stress.
33
34
35
36
37

38 **Cell Surface Imaging**

39 As the major phospholipid bilayer components PC and PE change in response to CMC-Cu
40 exposure, the focus shifted to imaging the cellular damage and surface morphology in high-
41 resolution detail by employing scanning electron microscopy (SEM). With the use of SEM, cell
42 surfaces were visualized prior to and post-CMC-Cu treatment. Deformities in the cell surface
43 resembled large invaginations post CMC-Cu exposure, as compared to the round and smooth cells
44 grown in YM media (Figure 4). Log-phase cells grown in YM media were circular and oval in
45 appearance (Figure 4A). The log phase cells were grown in YM with 157 μM CMC-Cu had surface
46 deformations that are distinguished by red arrows (Figure 4B). Two images were chosen to be
47 representative of treated and untreated population differences at 5,000 x magnification displaying
48 the cellular surfaces of approximately 100 cells. At a higher 10,000 x magnification, varying
49 degrees of cell surface invaginations on both mother and daughter cells (Figure 4C) were found.
50 Ethanol treatment has been shown to produce a similar abnormal cell surface phenotype in yeast
51 when visualized by electron micrographs¹¹⁴. These major alterations to the cellular structure have
52 previously been used as a marker in characterizing novel antimicrobial treatments^{115,116}. The
53 previous report on CMC-Cu's toxicity to *S. cerevisiae* provided evidence supporting endocytosis
54
55
56
57
58
59
60




Figure 4 **Scanning Electron Micrographs of Yeast's Cellular Surface.** (A) Normal log-phase cells imaged at 5,000 x magnification with a smooth round or oblong surface grown in YM media without treatments. (B) Deformed log-phase cells imaged at 5,000 x magnification post CMC-Cu treatment. Surface invaginations shown with red arrows. (C) Normal log-phase cells imaged at 10,000 x magnification with a smooth round or oblong surface grown in YM media without treatments. (D) Close view of cellular deformities at 10,000 x magnification post CMC-Cu treatment. of CMC-Cu by arrestins²⁸. Here, the membrane curvature shown on the SEM micrographs appear not to be endocytosis vesicles because of the micrometer size of many of the invagination. Some of these invaginations alter the entire morphology of the yeast cell so much so that they resemble mammalian red blood cells. These abnormal morphologies of the cellular structure are indicative of cell surface damage. Previous reports show nanometer sized vesicles associated with actin patches via transmission electron microscopy (TEM)^{117,118}. It is unlikely that these are a consequence of actin patches/ endocytosis, but the potential remains the that attempted endocytosis may be an antecedent to these invaginations. Direct membrane curvature by phospholipid modification¹¹⁹ has supporting evidence from the lipid profiling and lipid peroxidation results shown here. Prior research concerning the location of CMC-Cu stained with Fluorescein isothiocyanate (FITC) suggested an association with the cellular surface for both CMC-Cu and CMC treatments²⁸. Findings from the SEM images further support cell surface damage owing to membrane lipid peroxidation as the primary process by which CMC-Cu exerts its toxicity.

1
2
3 *S. cerevisiae* was chosen as a model system to investigate the nanotoxicity of the CMC-Cu
4 exposures because of its genetic tractability, conserved genome, and exceptional wealth of
5 experimental resources¹²⁰. In *S. cerevisiae* arrestin knockouts, *aly1* and *aly2*, are viable when
6 treated with CMC-Cu, unlike soluble copper²⁸. This supports a role for endocytosis of CMC-Cu²⁸.
7 Arrestins have been suggested as a general model for transporter regulation^{121,122}. Yeast α -arrestins
8 are intracellular proteins that target specific plasma membrane proteins for the endocytic system¹²³
9 including metal transporter Smf1¹²². Once arrestins associate with plasma membrane proteins,
10 ubiquitin-conjugating proteins are recruited. Ubiquitinated cargo is claimed for endocytosis and
11 transfers into the vacuole for degradation via both clathrin-independent and clathrin-mediated
12 endocytosis¹²⁴. *S. cerevisiae* has a small ellipsoid, 60 - 30 nm in diameter, endocytic vesicle¹²⁵.
13 Endocytosis internalizes cargo from the plasma membrane and has a critical role in nutrient uptake,
14 damaged protein turnover, membrane composition, and the response to extracellular signals. The
15 organization and proper composition of the plasma membrane are maintained by endocytic
16 downregulation of plasma membrane proteins during surface remodeling.
17
18
19
20
21

22 Conclusions

23
24 While performing an investigation into the nanotoxicological influence of CMC-Cu on metal
25 homeostasis, ROS production, lipid interaction, cellular morphology, and genotoxicity several
26 results were uncovered while using the *S. cerevisiae* model system. Metal homeostasis between
27 zinc and copper becomes unbalanced, increasing Cu content and decreasing Zn content, in
28 sensitive yeast strains upon treatment with CMC-Cu. Unbalanced Zn/ Cu metal homeostasis acts
29 as a secondary nanotoxicological process during CMC-Cu exposure. This unbalance is possibly
30 owing to the single nucleotide polymorphisms (SNPs) of *ZRT2* between genetically diverse yeast
31 strains²⁸, mis-metallation, or ionic mimicry. Exposure to CMC-Cu produces ROS that did not
32 indicate DNA damage but did suggest lipid peroxidation. Further exploration revealed that CMC-
33 Cu altered the major membrane phospholipids, PC and PE, and depleted TG lipids that act to
34 balance fatty acid saturation. This interaction between PC, PE, and TG suggest CMC-Cu has an
35 influence on the Kennedy Pathway. These findings align with literature associating lipid damage
36 with copper's antimicrobial mode of toxicity and Cu's interaction with PE and PC ,the major
37 membrane phospholipid bilayer components^{13,36,126}. The findings on CMC-Cu interaction with PC
38 and PE adds to the limited body of research pertaining to coppers influence on biological lipids.
39 Moreover, inspection of a detailed scanning electron micrograph showed an abnormal cellular
40 morphology induced by CMC-Cu treatment. The visualized cellular surface disfigurement
41 provides supporting evidence for surface membrane damage as the primary mechanism of action
42 of CMC-Cu exposure in *S. cerevisiae*.
43
44
45
46

47 The previous study provided evidence that CMC-Cu physically interacts with the cellular surface
48 and that α -arrestins Aly1 and Aly2 facilitate endocytosis of the copper nanoparticles into the cell²⁸.
49 An endocytosis mechanism likely attempts to partially or fully import CMC-Cu. Perhaps this
50 endocytosis event disfigures the cellular morphology as an antecedent or consequence of CMC-
51 Cu's physical interaction. Cumulatively, this evidence suggests CMC-Cu nanotoxicity occurs via
52 localized damage primarily to the cellular membrane with secondary damages occurring via
53 disruption of metal homeostasis and disruption of cellular functions likely in or near the vacuole
54 and mitochondria. Thus far, the difference in antioxidant rescue suggests an exogenous
55
56
57
58
59
60

1
2
3 toxicological aspect²⁸, knockouts of arrestins rescue suggest association with an endocytosis
4 event²⁸, high lipid peroxidation levels, high ROS levels, unbalanced Cu/ Zn homeostasis, and their
5 unique influence on membrane lipids separates CMC-Cu from CuSO₄ There are also many
6 overlaps in the toxicity and nanotoxicity of copper, such as the genetically diverse yeast strains'
7 sensitivity to soluble copper is also mirrored by their sensitivity to CMC-Cu²⁸. This is likely from
8 the genetic and transcriptional regulation of metallothiones such as Cup1²⁸. As nanotechnology
9 evolves to synthesize advanced hybrid nanomaterials and their ubiquity throughout society
10 increases, the demand for understanding biology's interaction with these materials will mature.
11
12

13 Figure Legends

14
15
16 **Figure 1. Copper and Zinc Metal Homeostasis Measured by Inductively Coupled Plasma –**
17 **Optical Emissions Spectroscopy During CMC-Cu Toxicity.** Sensitive strain YJM789 (A) and
18 resistant strain BY4741 (B) were harvested after 90-minute treatments with CMC-Cu or CuSO₄.
19 (A) YJM789 has a significant increase in cell-associated copper with CMC-Cu treatment and a
20 decrease in cellular zinc. (B) BY4741 showed an increase of cellular copper with CMC-Cu
21 treatment, no change to zinc concentrations. Statistical analysis performed via one-way ANOVA
22 with a post hoc Tukey HSD analysis (p=0.05). ND= Not detected.
23
24

25 **Figure 2. Cellular Toxicity Profiles Including ROS Generation and Biomolecule Damage.** (A)
26 ROS measurement by DCFDA fluorescence intensity showing H₂O₂ and CMC-Cu producing
27 higher amounts of ROS than YM or CuSO₄. Statistical analysis performed via one-way ANOVA
28 with Tukey HSD post-hoc analysis that suggested that YM and CuSO₄ did not differ significantly
29 while both H₂O₂ and CMC-Cu were different from all other samples (p=0.05). (B) DNA damage
30 qualitative assessment over time by PFGE comparing cells grown in YM media to H₂O₂ and CMC-
31 Cu treatments. Blue represents cells grown in YM media, red represents H₂O₂ treated cells, green
32 represents CMC-Cu treated cells. H₂O₂ Chromosomal bands progressively get more ill-defined
33 after 15 minutes while CMC-Cu bands remain defined. (C) Lipid peroxidation measured by MDA
34 production via TBARS assay of cells grown in YM media or after 90-minute treatment with H₂O₂,
35 CMC-Cu, or CuSO₄. ANOVA statistical analysis was performed with Tukey-HSD post-hoc
36 analysis and a p-value cut off of 0.05.
37
38
39

40 **Figure 3. Lipid Metabolic Profiling in Response to CMC-Cu Treatment.** (A) Partial least
41 squares discriminant analysis (PLS-DA) showing component 1 and component 2 separated all
42 treatments but YM and CMC-Cu. (B) PLS-DA showing component 1 and component 3 separated
43 all treatments but YM and CMC-Cu, as well as CMC-Cu and CuSO₄. Taken together, components
44 1, 2, and 3 provide a 3-dimensional separation of all treatments based on their lipid profiles. (C)
45 Heatmap of the top 10 metabolites used in profiling yeast treatment groups. Samples are divided
46 into columns, compounds are divided by rows, and the color is indicative of relative abundance.
47 Which was calculated via MetaboAnalyst hierarchical heatmap clustering analysis (clustering
48 distance using euclidean, and clustering algorithm using ward D). (D) Quantitative growth assays
49 of BY4742 (wildtype) and *scw10* isogenic mutant in YM, YM+CMC-Cu, and YM+CMC-Cu with
50 glutathione (GSH). The average of four biological replicates were graphed with standard error
51 after 24 hours of growth.
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 4. Scanning Electron Micrographs of Yeast's Cellular Surface.** (A) Normal log-phase
4 cells imaged at 5,000 x magnification with a smooth round or oblong surface grown in YM media
5 without treatments. (B) Deformed log-phase cells imaged at 5,000 x magnification post CMC-Cu
6 treatment. Surface invaginations shown with red arrows. (C) Normal log-phase cells imaged at
7 10,000 x magnification with a smooth round or oblong surface grown in YM media without
8 treatments. (D) Close view of cellular deformities at 10,000 x magnification post CMC-Cu
9 treatment.
10
11

12 **Figure S1. Copper Homeostasis During CMC-Cu Toxicity Represented in Treatment**
13 **Groups.** (A) Copper levels after normal log phase cell growth in YM. (B) Copper levels after
14 CMC-Cu treatment. (C) Copper levels after CuSO₄ treatment. Red bars represent the resistant
15 strain BY4741. Silver bars represent the sensitive strain YJM789.
16
17

18 **Figure S2. Cellular ROS Generation Over Time.** ROS measurement by DCFDA fluorescence
19 intensity showing H₂O₂ and CMC-Cu producing higher amounts of ROS than YM or CuSO₄.
20 Endpoint (90 min) statistical analysis performed via one-way ANOVA with Tukey HSD post-hoc
21 analysis that suggested that YM and CuSO₄ did not differ significantly while both CMC-Cu and
22 H₂O₂ were different from all other samples (p=0.05).
23
24

25 **Figure S3. Lipidomic Statistics for CMC-Cu Treatment.** (A) Unsupervised principal
26 component analysis (PCA) of yeast grown in YM and treated with CMC-Cu, CuSO₄, or YM media
27 showing incomplete separation of all treatments. (B) Loading plot for the PCA seen in part B. (C)
28 Important compounds identified by One-way ANOVA with a Tukey HSD post-hoc analysis. The
29 significance is presented on the y-axis with red dots indicating a significance greater than p=0.05
30 as indicated by the dashed line and insignificant dots in green. Of the compounds detected, select
31 compounds of importance as identified in the heatmap analysis are labeled by name.
32
33

34 **Figure S4. Whole Lipidome Heatmap for CMC-Cu Treatment.** Color indicates the relative
35 abundance on a Log₂ fold change of the complete heatmap by each sample.
36
37

38 **Table S1. Normalized Gas Chromatography Electrospray Ionization Mass Spectrometry**
39 **Data.** Column headers contain the ID compound and the rows are organized by the individual
40 samples.
41

42 **Table S2. Loading Matrix for PLS-DA Lipidomic Assay.** Column headers contain each
43 principal component and the rows are organized by the individual ID compounds.
44
45

46 **Acknowledgments:** MJW was supported by the Nation Science Foundation's Integrative
47 Graduate Education and Research Traineeship: Research and Education in Nanotoxicology at
48 West Virginia University (IGERT:REN@WVU) award number 1144676. We acknowledge
49 Amaury Pupo Meriño for help with the GC-ESI/MS study and analysis, Marcela Redigolo for help
50 using the electron microscope, Dr. Jonathan Cumming for help with the ICP-OES, Dr. Gloria
51 Oporto for generously supplying the nanoparticles, Dr. Kang Mo Ku for help with the
52 metabolomics studies, and The WVU Genomics Corps for use of their instruments.
53
54
55
56
57
58
59
60

The authors state no conflict of interest. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.

References

- 1 J. Gabbay, G. Borkow, J. Mishal, E. Magen, R. Zatzoff and Y. Shemer-Avni, *J. Ind. Text.*, 2006, **35**, 323–335.
- 2 H. Palza, *Int. J. Mol. Sci.*, 2015, **16**, 2099–2116.
- 3 N. Cioffi, L. Torsi, N. Ditaranto, G. Tantillo, L. Ghibelli, L. Sabbatini, T. Bleve-Zacheo, M. D'Alessio, P. G. Zambonin and E. Traversa, *Chem. Mater.*, 2005, **17**, 5255–5262.
- 4 G. Borkow and J. Gabbay, *Curr. Chem. Biol.*, 2009, **3**, 272–278.
- 5 J. J. Hostynek and H. I. Maibach, *Dermatol. Ther.*, 2004, **17**, 328–333.
- 6 J. A. Lemire, J. J. Harrison and R. J. Turner, *Nat. Rev. Microbiol.*, 2013, **11**, 371–384.
- 7 H. E. Allen, T. D. Brisbin and R. H. Hall, *Environ. Sci. Technol.*, 1980, **14**, 441–443.
- 8 H. E. Allen and D. J. Hansen, *Water Environ. Res.*, 1996, **68**, 42–54.
- 9 L. A. Finney and T. V. O'Halloran, *Science (80-.)*, 2003, **300**, 931–936.
- 10 M. P. Murphy, *Biochem. J.*, 2009, **417**, 1–13.
- 11 J. Zhang, X. Wang, V. Vikash, Q. Ye, D. Wu, Y. Liu and W. Dong, *Oxid. Med. Cell. Longev.*, 2016, **2016**, 1–18.
- 12 S. Avery, N. Howlett and S. Radice, *Appl. Envir. Microbiol.*, 1996, **62**, 3960–3966.
- 13 M. Suwalsky, B. Ungerer, L. Quevedo, F. Aguilar and C. P. Sotomayor, *J. Inorg. Biochem.*, 1998, **70**, 233–238.
- 14 E. Baatrup, *Comp. Biochem. Physiol. Part C, Comp.*, 1991, **100**, 253–257.
- 15 K. L. Haas and K. J. Franz, *Chem. Rev.*, 2009, **109**, 4921–4960.
- 16 Z. Ma, F. E. Jacobson and D. P. Giedroc, *October*, 2009, **109**, 4644–4681.
- 17 K. J. Waldron, J. C. Rutherford, D. Ford and N. J. Robinson, *Nature*, 2009, 460, 823–830.
- 18 K. J. Waldron and N. J. Robinson, *Nat. Rev. Microbiol.*, 2009, **7**, 25–35.
- 19 C. Andreini, I. Bertini and A. Rosato, *Bioinformatics*, 2004, **20**, 1373–1380.
- 20 H. Irving and R. J. P. Williams, *J. Chem. Soc.*, 1953, 3192–3210.
- 21 Y. Wang, E. Weisenhorn, C. W. MacDiarmid, C. Andreini, M. Bucci, J. Taggart, L. Banci, J. Russell, J. J. Coon and D. J. Eide, *metallomics*, 2018, **10**, 1755–1776.
- 22 L. T. Jensen, M. Ajua-Alemanji and V. C. Culotta, *J. Biol. Chem.*, 2003, **278**, 42036–42040.
- 23 C. W. MacDiarmid, L. A. Gaither and D. Eide, *EMBO J.*, 2000, **19**, 2845–2855.
- 24 L. Li, O. S. Chen, D. M. V. Ward and J. Kaplan, *J. Biol. Chem.*, 2001, **276**, 29515–29519.
- 25 Y. Habibi, L. A. Lucia and O. J. Rojas, *Chem. Rev.*, 2010, **110**, 3479–3500.
- 26 C. W. Owens, G. S. Oporto, B. C. G. Söderberg and K. E. Lambson, *J. Nanomater.*, , DOI:10.1155/2017/9461615.
- 27 T. Zhong, G. S. Oporto, J. Armstrong, J. Jaczynski and A. T. Tesfai, *Wood Fiber Sci.*, 2013, **45**, 215–222.
- 28 X. Rong-Mullins, M. J. Winans, J. B. Lee, Z. R. Lonergan, V. A. Pilolli, L. M. Weatherly, T. W. Carmenzind, L. Jiang, J. R. Cumming, G. S. Oporto and J. E. G. G. Gallagher, *Metallomics*, 2017, **9**, 1304–1315.

- 1
2
3 29 M. Hassanzadeh, R. Sabo, A. Rudie, R. Reiner, R. Gleisner and G. S. Oporto, *J.*
4 *Nanomater.*, , DOI:10.1155/2017/2102987.
5
6 30 M. J. Winans, J. E. G. Gallagher, J. Jaczynski and G. Oporto, *bioRxiv*, 2019, 783076.
7 31 T. Zhong, G. S. Oporto, J. Jaczynski and C. Jiang, *Biomed Res. Int.*, 2015, **2015**, 456834.
8 32 C. Jiang, G. S. S. Oporto, T. Zhong and J. Jaczynski, *Cellulose*, 2015, **23**, 1–10.
9 33 K. Kasemets, A. Ivask, H. C. Dubourguier and A. Kahru, *Toxicol. Vitro.*, 2009, **23**, 1116–
10 1122.
11 34 H. L. Karlsson, P. Cronholm, J. Gustafsson and L. Möller, *Chem. Res. Toxicol.*, 2008, **21**,
12 1726–1732.
13 35 K. Midander, P. Cronholm, H. L. Karlsson, K. Elihn, L. Möller, C. Leygraf and I. O.
14 Wallinder, *Small*, 2009, **5**, 389–399.
15 36 S. S. V. Avery, N. N. G. Howlett and S. Radice, *Appl. Environ. Microbiol.*, 1996, **62**,
16 3960–3966.
17 37 A. Pupo, M. C. Ayers, Z. N. Sherman, R. J. Vance, J. R. Cumming and J. E. G. G.
18 Gallagher, *Biol. Trace Elem. Res.*, 2019, 1–12.
19 38 L. C. Kobashigawa, Y. C. Xu, J. F. Padbury, Y. T. Tseng and N. Yano, *PLoS One*, ,
20 DOI:10.1371/journal.pone.0104888.
21 39 S. D. Bourque and V. I. Titorenko, *J. Vis. Exp.*, 2009, e1513.
22 40 A. Pupo, K. M. Ku and J. E. G. Gallagher, *PLoS One*, ,
23 DOI:10.1371/journal.pone.0223909.
24 41 C. A. Smith, E. J. Want, G. O’Maille, R. Abagyan, G. Siuzdak, Colin A. Smith, Elizabeth
25 J. Want, Grace O’Maille, and Ruben Abagyan and G. Siuzdak*, - *Anal. Chem.*, 2006,
26 **78**, 79.
27 42 P. Du, W. A. Kibbe and S. M. Lin, *Bioinformatics*, 2006, **22**, 2059–2065.
28 43 B. Zhou, J. Wang and H. W. Resson, *PLoS One*, 2012, **7**, e40096.
29 44 D. S. Wishart, Y. D. Feunang, A. Marcu, A. C. Guo, K. Liang, R. Vázquez-Fresno, T.
30 Sajed, D. Johnson, C. Li, N. Karu, Z. Sayeeda, E. Lo, N. Assempour, M. Berjanskii, S.
31 Singhal, D. Arndt, Y. Liang, H. Badran, J. Grant, A. Serra-Cayuela, Y. Liu, R. Mandal, V.
32 Neveu, A. Pon, C. Knox, M. Wilson, C. Manach and A. Scalbert, *Nucleic Acids Res.*,
33 2018, **46**, D608–D617.
34 45 C. Guijas, J. R. Montenegro-Burke, X. Domingo-Almenara, A. Palermo, B. Warth, G.
35 Hermann, G. Koellensperger, T. Huan, W. Uritboonthai, A. E. Aisporna, D. W. Wolan,
36 M. E. Spilker, H. P. Benton and G. Siuzdak, *Physiol. Behav.*, 2018, **5**, 3156–3164.
37 46 Q. Cui, I. A. Lewis, A. D. Hegeman, M. E. Anderson, J. Li, C. F. Schulte, W. M. Westler,
38 H. R. Eghbalnia, M. R. Sussman and J. L. Markley, *Nat. Biotechnol.*, 2008, **26**, 162–164.
39 47 E. Fahy, M. Sud, D. Cotter and S. Subramaniam, *Nucleic Acids Res.*, 2007, **35**, 606–612.
40 48 M. Ramirez-Gaona, A. Marcu, A. Pon, A. C. Guo, T. Sajed, N. A. Wishart, N. Karu, Y. D.
41 Feunang, D. Arndt and D. S. Wishart, *Nucleic Acids Res.*, 2017, **45**, D440–D445.
42 49 S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, Q. Li, B. A. Shoemaker, P. A.
43 Thiessen, B. Yu, L. Zaslavsky, J. Zhang and E. E. Bolton, *Nucleic Acids Res.*, 2019, **47**,
44 D1102–D1109.
45 50 J. Xia, I. V. Sinelnikov, B. Han and D. S. Wishart, *Nucleic Acids Res.*, 2015, **43**, W251–
46 W257.
47 51 D. J. Eide, *Biochim. Biophys. Acta - Mol. Cell Res.*, 2006, **1763**, 711–722.
48 52 C. A. Fierke and R. B. Thompson, *BioMetals*, 2001, **14**, 205–222.
49 53 J. L. Vinkenborg, M. S. Koay and M. Merckx, *Curr. Opin. Chem. Biol.*, 2010, **14**, 231–237.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54 P. J. Dittmer, J. G. Miranda, J. A. Gorski and A. E. Palmer, *J. Biol. Chem.*, 2009, **284**,
4 16289–16297.
5
6 55 C. Devirgiliis, C. Murgia, G. Danscher and G. Perozzi, *Biochem. Biophys. Res. Commun.*,
7 2004, **323**, 58–64.
8 56 A. Krężel and W. Maret, *Int. J. Mol. Sci.*, 2017, **18**, 1–20.
9 57 C. W. MacDiarmid, *EMBO J.*, 2000, **19**, 2845–2855.
10 58 T. W. Clarkson, *Annu. Rev. Pharmacol. Toxicol.*, 1993, 545–571.
11 59 C. M. Lin and D. J. Kosman, *J. Biol. Chem.*, 1990, **265**, 9194–9200.
12 60 C. M. Lin, B. F. Crawford and D. J. Kosman, *J. Gen. Microbiol.*, 1993, **139**, 1617–1626.
13 61 S. J. Stohs and D. Bagchi, *Free Radic. Biol. Med.*, 1995, **18**, 321–336.
14 62 M. Valko, H. Morris and M. T. D. Cronin, *Curr. Med. Chem.*, 2005, **12**, 1161–1208.
15 63 L. Macomber and J. A. Imlay, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 8344–8349.
16 64 F. F. Xu and J. A. Imlay, *Appl. Environ. Microbiol.*, 2012, **78**, 3614–3621.
17 65 M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic and M. Mazur, *Chem. Biol. Interact.*,
18 2006, **160**, 1–40.
19
20 66 M. Fauchon, G. Lagniel, J. C. Aude, L. Lombardia, P. Soularue, C. Petat, G. Marguerie,
21 A. Sentenac, M. Werner and J. Labarre, *Mol. Cell*, 2002, **9**, 713–723.
22 67 K. Helbig, C. Grosse and D. H. Nies, *J. Bacteriol.*, 2008, **190**, 5439–5454.
23 68 K. Helbig, C. Bleuel, G. J. Krauss and D. H. Nies, *J. Bacteriol.*, 2008, **190**, 5431–5438.
24 69 Y. Zhao, P. K. K. Strobe, S. G. G. Kozmin, J. H. H. McCusker, F. S. S. Dietrich, R. J. J.
25 Kokoska and T. D. D. Petes, *G3 (Bethesda)*, 2014, **4**, 2259–2269.
26 70 M. Karin, R. Najarian, A. Haslinger, P. Valenzuela, J. Welch, S. Fogel, R. Najariant, A.
27 Haslinger, P. Valenzuelat and J. Welcht, *Proc Natl Acad Sci U S A*, 1984, **81**, 337–341.
28 71 B. N. Ames and L. S. Gold, *Mutat. Res. - Fundam. Mol. Mech. Mutagen.*, 1991, **250**, 3–
29 16.
30 72 B. Halliwell and O. I. Aruoma, *Fed. Eur. Biochem. Soc.*, 1991, **281**, 9–19.
31 73 G. G. Perrone, S. X. Tan and I. W. Dawes, *Biochim. Biophys. Acta - Mol. Cell Res.*, 2008,
32 **1783**, 1354–1368.
33 74 F. Madeo, E. Fröhlich, M. Ligr, M. Grey, S. J. Sigrist, D. H. Wolf, K. Fröhlich, P. Institut,
34 U. Tübingen, A. Institut, I. Biochemie, U. Stuttgart, W. Goethe-universität and F. Main,
35 1999, **145**, 757–767.
36 75 Q. Liang and B. Zhou, *Mol. Biol. Cell*, 2007, **18**, 4741–9.
37 76 F. Madeo, E. Fröhlich and K. U. Fröhlich, *J. Cell Biol.*, 1997, **139**, 729–734.
38 77 R. Reekmans, K. De Smet, C. Chen, P. Van Hummelen and R. Contreras, *FEMS Yeast*
39 *Res.*, 2005, **5**, 711–725.
40 78 W. Jian, J. S. Arora, T. Oe, V. V. Shuvaev and I. A. Blair, *Free Radic. Biol. Med.*, 2005,
41 **39**, 1162–1176.
42 79 B. Zhivotovsky and G. Kroemer, *Nat. Rev. Mol. Cell Biol.*, 2004, **5**, 752–762.
43 80 W. A. Pryor, *Free Radic. Biol. Med.*, 1989, **7**, 177–178.
44 81 H. Esterbauer and K. H. Cheeseman, *Methods Enzymol.*, 1990, **186**, 407–421.
45 82 A. Ayala, M. F. Muñoz and S. Argüelles, *Oxid. Med. Cell. Longev.*, 2014, 1–31.
46 83 H. Yin, L. Xu and N. A. Porter, *Chem. Rev.*, 2011, **111**, 5944–5972.
47 84 A. W. Girotti, *J. Lipid Res.*, 1998, **39**, 1529–1542.
48 85 M. V. Evans, H. E. Turton, C. M. Grant and I. W. Dawes, *J. Bacteriol.*, 1998, **180**, 483–
49 490.
50 86 A. Negre-Salvayre, C. Coatrieux, C. Ingueneau and R. Salvayre, *Br. J. Pharmacol.*, 2008,
51
52
53
54
55
56
57
58
59
60

- 1
2
3 **153**, 6–20.
- 4 87 B. Halliwell and J. M. C. Gutteridge, *Biochem. J.*, 1984, **219**, 1–14.
- 5 88 M. Slaba, P. Bernat, S. Rózsalska, J. Nykiel and J. Długoński, *Acta Biochim. Pol.*, 2013,
6 **60**, 695–700.
- 7 89 M. F. Renne and A. I. P. M. de Kroon, *FEBS Lett.*, 2018, **592**, 1330–1345.
- 8 90 D. Toomre, K. Simons and D. Toomre, *Nat. Rev. Mol. Cell Biol.*, 2000, **1**, 1.
- 9 91 G. Van Meer, D. R. Voelker and G. W. Feigenson, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**,
10 112–124.
- 11 92 O. Tehlivets, K. Scheuringer and S. D. Kohlwein, *Biochim. Biophys. Acta - Mol. Cell Biol.*
12 *Lipids*, 2007, **1771**, 255–270.
- 13 93 D. Ackerman, S. Tumanov, B. Qiu, E. Michalopoulou, M. Spata, A. Azzam, H. Xie, M. C.
14 Simon and J. J. Kamphorst, *Cell Rep.*, 2018, **24**, 2596-2605.e5.
- 15 94 T. Eisenberg and S. Büttner, *FEMS Yeast Res.*, 2014, **14**, 179–197.
- 16 95 T. Czabany, K. Athenstaedt and G. Daum, *Biochim. Biophys. Acta - Mol. Cell Biol.*
17 *Lipids*, 2007, **1771**, 299–309.
- 18 96 A. Wolf, P. Weir, P. Segar, J. Stone and J. Shield, *Lancet*, 2001, **357**, 606–607.
- 19 97 R. Santer, R. Fingerhut, U. Lässker, P. J. Wightman, D. R. Fitzpatrick, B. Olgemöller and
20 A. A. Roscher, *Clin. Chem.*, 2003, **49**, 660–662.
- 21 98 N. Napolitano, V. Wiley and J. J. Pitt, *J. Inherit. Metab. Dis.*, 2004, **27**, 465–471.
- 22 99 A. Rötig and A. Munnich, *J. Am. Soc. Nephrol.*, 2003, **14**, 2995–3007.
- 23 100 J. R. Harris and E. J. (Eds. . Boekema, *Membrane Protein Complexes: Structure and*
24 *Function*, 2018, vol. 87.
- 25 101 P. A. A. Cobine, L. D. D. Ojeda, K. M. M. Rigby and D. R. R. Winge, *J. Biol. Chem.*,
26 2004, **279**, 14447–14455.
- 27 102 S. C. Leary, D. R. Winge and P. A. Cobine, *Biochim. Biophys. Acta - Mol. Cell Res.*,
28 2009, **1793**, 146–153.
- 29 103 V. V. Mossine and T. P. Mawhinney, *1-Amino-1-deoxy-d-fructose ('Fructosamine') and*
30 *its Derivatives*, 2010, vol. 64.
- 31 104 V. V. Mossine and T. P. Mawhinney, *J. Agric. Food Chem.*, 2007, **55**, 10373–10381.
- 32 105 B. Gyurcsik, T. Gajba, L. Nagy, K. Burger, A. Rockenbauer and L. Korecz, *Inorganica*
33 *Chim. Acta*, 1993, **1**, 57–66.
- 34 106 A. Naranuntarat, L. T. Jensen, S. Pazicni, J. E. Penner-Hahn and V. C. Culotta, *J. Biol.*
35 *Chem.*, 2009, **284**, 22633–22640.
- 36 107 L. M. Buu, Y. C. Chen and F. J. S. Lee, *J. Biol. Chem.*, 2003, **278**, 17203–17209.
- 37 108 P. McGraw and S. A. Henry, *Genetics*, 1989, **122**, 317–330.
- 38 109 I. D. Schlatter, M. Meira, V. Ueberschlag, D. Hoepfner, R. Movva and N. E. Hynes, *PLoS*
39 *One*, , DOI:10.1371/journal.pone.0032501.
- 40 110 A. M. Avery and S. V. Avery, *J. Biol. Chem.*, 2001, **276**, 33730–33735.
- 41 111 M. J. Kuranda and P. W. Robbins, *J. Biol. Chem.*, 1991, **266**, 19758–19767.
- 42 112 C. O'Conalláin, M. T. Doolin, C. Taggart, F. Thornton and G. Butler, *Mol. Gen. Genet.*,
43 1999, **262**, 275–282.
- 44 113 C. Cappellaro, V. Mrsa and W. Tanner, *J. Bacteriol.*, 1998, **180**, 5030–5037.
- 45 114 Y. Luo, J. Wang, B. Liu, Z. Wang, Y. Yuan and T. Yue, *PLoS One*, ,
46 DOI:10.1371/journal.pone.0136045.
- 47 115 S. Vijayarathna, Z. Zakaria, Y. Chen, L. Y. Latha, J. R. Kanwar and S. Sasidharan,
48 *Molecules*, 2012, **17**, 4860–4877.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 116 S. L. Jothy, Z. Zakariah, Y. Chen and S. Sasidharan, *Molecules*, 2012, **17**, 6997–7009.
4 117 F. Z. Idrissi, A. Blasco, A. Espinal and M. I. Geli, *Proc. Natl. Acad. Sci. U. S. A.*, ,
5 DOI:10.1073/pnas.1202789109.
6 118 C. Buser and D. G. Drubin, *Microsc Microanal*, 2013, **19**, 381–392.
7 119 I. K. Jarsch, F. Daste and J. L. Gallop, *J. Cell Biol.*, 2016, **214**, 375–387.
8 120 A. A. Duina, M. E. Miller and J. B. Keeney, *Genetics*, 2014, **197**, 33–48.
9 121 E. Nikko and H. R. B. Pelham, *Traffic*, 2009, **10**, 1856–1867.
10 122 E. Nikko, J. A. Sullivan and H. R. B. Pelham, *EMBO Rep.*, 2008, **9**, 1216–1221.
11 123 C. H. Lin, J. A. MacGurn, T. Chu, C. J. Stefan and S. D. Emr, *Cell*, 2008, **135**, 714–725.
12 124 D. C. Prosser, A. E. Pannunzio, J. L. Brodsky, J. Thorner, B. Wendland and A. F.
13 O’Donnell, *J. Cell Sci.*, 2015, **128**, 4220–4234.
14 125 W. Kukulski, M. Schorb, M. Kaksonen and J. A. G. Briggs, *Cell*, 2012, **150**, 508–520.
15 126 M. E. Letelier, A. M. Lepe, M. Faúndez, J. Salazar, R. Marín, P. Aracena and H. Speisky,
16 *Chem. Biol. Interact.*, 2005, **151**, 71–82.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60